Probiotics in Gut Health and Immunity: Mechanisms and Clinical Evidence
DOI:
https://doi.org/10.12775/JEHS.2026.91.70798Keywords
probiotics, gut microbiota, intestinal barrier function, tight junctions, regulatory T cells, Clostridioides difficile, functional gastrointestinal disorders, atopic dermatitis, childhood asthma, antibiotic-associated diarrhea, Lactobacillus, Bifidobacterium, immune tolerance, NF-κB pathway, multistrain formulationsAbstract
Background. Probiotics are live microorganisms that support human health mainly by influencing the gut microbiota. They help maintain the integrity of the intestinal barrier and play an important role in regulating immune responses. Their growing clinical relevance is linked to conditions associated with microbiota imbalance.
Aim. The aim of this review was to present the main mechanisms of probiotic action and to assess their clinical effectiveness in selected gastrointestinal, infectious, and allergic diseases.
Material and methods. This narrative review is based on data from randomized controlled trials and meta-analyses focusing on both molecular mechanisms and clinical outcomes of probiotic use.
Results. Probiotics improve intestinal barrier function by supporting tight junction proteins and reducing intestinal permeability. They also modulate immune responses by limiting inflammation and promoting regulatory pathways, including the induction of regulatory T cells. Clinical studies show that multistrain preparations, especially those containing Lactobacillus and Bifidobacterium, are effective in reducing the risk of antibiotic-associated diarrhea and Clostridioides difficile infection. They also help relieve symptoms of functional gastrointestinal disorders and improve outcomes in allergic diseases such as atopic dermatitis and childhood asthma. Overall, probiotics are well tolerated and safe.
Conclusions. Probiotics can be a valuable supportive therapy in disorders related to microbiota imbalance. Further studies should focus on better matching specific strains to individual patients in order to increase treatment effectiveness.
References
[1] L. Ontario, “Food and Agriculture Organization of the United Nations World Health Organization”, Accessed: Jan. 23, 2026. [Online]. Available: http://www.fao.org/es/ESN/Probio/probio.htm
[2] P. Markowiak and K. Ślizewska, “Effects of Probiotics, Prebiotics, and Synbiotics on Human Health,” Nutrients, vol. 9, no. 9, p. 1021, Sep. 2017, doi: 10.3390/NU9091021.
[3] T. Kumari, K. K. Bag, A. B. Das, and S. C. Deka, “Synergistic role of prebiotics and probiotics in gut microbiome health: Mechanisms and clinical applications,” Food Bioengineering, vol. 3, no. 4, pp. 407–424, Dec. 2024, doi: 10.1002/FBE2.12107;SUBPAGE:STRING:FULL.
[4] T. J. ASHAOLU, B. GREFF, and L. VARGA, “Action and immunomodulatory mechanisms, formulations, and safety concerns of probiotics,” Biosci. Microbiota Food Health, vol. 44, no. 1, p. 4, 2024, doi: 10.12938/BMFH.2024-006.
[5] S. Binda et al., “Criteria to Qualify Microorganisms as ‘Probiotic’ in Foods and Dietary Supplements,” Front. Microbiol., vol. 11, p. 563305, Jul. 2020, doi: 10.3389/FMICB.2020.01662/BIBTEX.
[6] M. M. Ferris, L. Subitoni Antonio, and R. Al-Sadi, “Probiotics and the intestinal tight junction barrier function,” Front. Cell Dev. Biol., vol. 13, p. 1671152, Dec. 2025, doi: 10.3389/FCELL.2025.1671152/FULL.
[7] K. R. Bergmann et al., “Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis,” American Journal of Pathology, vol. 182, no. 5, pp. 1595–1606, 2013, doi: 10.1016/j.ajpath.2013.01.013.
[8] R. Abdulqadir, R. Al-Sadi, M. Haque, Y. Gupta, M. Rawat, and T. Y. Ma, “Bifidobacterium bifidum Strain BB1 Inhibits Tumor Necrosis Factor-α–Induced Increase in Intestinal Epithelial Tight Junction Permeability via Toll-Like Receptor-2/Toll-Like Receptor-6 Receptor Complex–Dependent Stimulation of Peroxisome Proliferator-Acti…,” American Journal of Pathology, vol. 194, no. 9, pp. 1664–1683, Sep. 2024, doi: 10.1016/j.ajpath.2024.05.012.
[9] H. K. Kwon et al., “Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders,” Proc. Natl. Acad. Sci. U. S. A., vol. 107, no. 5, pp. 2159–2164, Feb. 2010, doi: 10.1073/PNAS.0904055107.
[10] S. Lavasani et al., “A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells,” PLoS One, vol. 5, no. 2, Feb. 2010, doi: 10.1371/JOURNAL.PONE.0009009.
[11] E. Lyn Lee et al., “Probiotics for the prevention of antibiotic-associated diarrhea – an umbrella review of meta-analyses of randomized controlled trials,” European Journal of Clinical and Experimental Medicine, vol. 23, no. 1, pp. 237–244, 2025, doi: 10.15584/EJCEM.2025.1.22.
[12] V. Hodzhev et al., “High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Adults: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial (SPAADA),” Open Forum Infect. Dis., vol. 11, no. 11, Nov. 2024, doi: 10.1093/OFID/OFAE615.
[13] H. Wanyama, T. S. Akhtar, and S. Abbas, “Probiotic use reduces the incidence of antibiotic-associated diarrhea among adult patients: a meta-analysis,” Prz. Gastroenterol., vol. 20, no. 1, p. 5, 2025, doi: 10.5114/PG.2025.148486.
[14] C. Goodman, G. Keating, E. Georgousopoulou, C. Hespe, and K. Levett, “Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis,” BMJ Open, vol. 11, no. 8, Aug. 2021, doi: 10.1136/BMJOPEN-2020-043054.
[15] R. Pattani, V. A. Palda, S. W. Hwang, and P. S. Shah, “Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis,” Open Medicine, vol. 7, no. 2, p. e56, 2013, Accessed: Jan. 24, 2026. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC3863752/
[16] A. Saviano et al., “The Efficacy of a Mix of Probiotics (Limosilactobacillus reuteri LMG P-27481 and Lacticaseibacillus rhamnosus GG ATCC 53103) in Preventing Antibiotic-Associated Diarrhea and Clostridium difficile Infection in Hospitalized Patients: Single-Center, Open-La…,” Microorganisms, vol. 12, no. 1, Jan. 2024, doi: 10.3390/MICROORGANISMS12010198.
[17] M. Simren, O. S. Palsson, and W. E. Whitehead, “Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice,” Curr. Gastroenterol. Rep., vol. 19, no. 4, Apr. 2017, doi: 10.1007/S11894-017-0554-0.
[18] Y. Zheng, L. Xu, S. Zhang, Y. Liu, J. Ni, and G. Xiao, “Effect of a probiotic formula on gastrointestinal health, immune responses and metabolic health in adults with functional constipation or functional diarrhea,” Front. Nutr., vol. 10, p. 1196625, Jul. 2023, doi: 10.3389/FNUT.2023.1196625/BIBTEX.
[19] W. Liao, M. Su, and D. Zhang, “A study on the effect of symbiotic fermented milk products on human gastrointestinal health: Double-blind randomized controlled clinical trial,” Food Sci. Nutr., vol. 10, no. 9, pp. 2947–2955, Sep. 2022, doi: 10.1002/FSN3.2890.
[20] Y. Wu, Y. Li, Q. Zheng, and L. Li, “The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis,” Nutrients 2024, Vol. 16, vol. 16, no. 13, Jul. 2024, doi: 10.3390/NU16132114.
[21] E. Li, J. Wang, B. Guo, and W. Zhang, “Effects of short-chain fatty acid-producing probiotic metabolites on symptom relief and intestinal barrier function in patients with irritable bowel syndrome: a double-blind, randomized controlled trial,” Front. Cell. Infect. Microbiol., vol. 15, 2025, doi: 10.3389/FCIMB.2025.1616066.
[22] H. J. Kim, H. Y. Kim, S. Y. Lee, J. H. Seo, E. Lee, and S. J. Hong, “Clinical efficacy and mechanism of probiotics in allergic diseases,” Korean J. Pediatr., vol. 56, no. 9, pp. 369–376, 2013, doi: 10.3345/KJP.2013.56.9.369.
[23] B. Foligne et al., “A key role of dendritic cells in probiotic functionality,” PLoS One, vol. 2, no. 3, Mar. 2007, doi: 10.1371/JOURNAL.PONE.0000313.
[24] P. D. S. M. A. de Andrade et al., “Efficacy of Probiotics in Children and Adolescents With Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Study,” Front. Nutr., vol. 8, p. 833666, Jan. 2022, doi: 10.3389/FNUT.2021.833666.
[25] B. Cukrowska et al., “The Effectiveness of Probiotic Lactobacillus rhamnosus and Lactobacillus casei Strains in Children with Atopic Dermatitis and Cow’s Milk Protein Allergy: A Multicenter, Randomized, Double Blind, Placebo Controlled Study,” Nutrients, vol. 13, no. 4, p. 1169, Apr. 2021, doi: 10.3390/NU13041169.
[26] C. F. Huang, W. C. Chie, and I. J. Wang, “Efficacy of Lactobacillus Administration in School-Age Children with Asthma: A Randomized, Placebo-Controlled Trial,” Nutrients 2018, Vol. 10, vol. 10, no. 11, Nov. 2018, doi: 10.3390/NU10111678.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Michał Filipski, Bartosz Wróbel, Lena Wójcik, Krzysztof Gadzalski, Konstancja Owczarenko, Kacper Szada-Borzyszkowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 42
Number of citations: 0
